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Abstract 
 
Objective: To investigate the impact of antirheumatic medications on salivary matrix 
metalloproteinase (MMP) -8 levels and MMP-8/TIMP (tissue inhibitor of MMPs)-1 ratio in patients 
with rheumatoid arthritis (RA) and periodontal findings during a 1-year follow-up.  
Materials and Methods: Salivary MMP-8 was measured by an immunofluorometric assay  and 
TIMP-1 by an enzyme-linked immunosorbent assay of 53 patients with early untreated RA (ERA), 
naïve to synthetic disease modifying antirheumatic drugs (DMARDs), of 28 patients with chronic 
RA (CRA), candidates for biologic DMARDs and of 43 age- and sex-matched controls. Periodontal 
health was evaluated by bleeding on probing (BOP), pocket depth (PD), and periodontal 
inflammatory burden index (PIBI). Examinations were conducted twice for RA patients and once 
for controls. 
Results: Salivary MMP-8 level and MMP-8/TIMP-1 ratio associated positively with PIBI in 
patients with chronic RA (MMP-8: p<0.001 at baseline, p=0.002 after follow-up; MMP-8/TIMP-1 
ratio p<0.001, p=0.003, respectively) and in controls (MMP-8: p=0.010, MMP-8/TIMP-1 ratio: 
p=0.010). Salivary MMP-8 levels were highest at the early stage of RA. The used DMARDs, 
synthetic or biologic, did not affect salivary MMP-8 concentrations.  
Conclusions: The use of synthetic or biologic DMARDs did not affect salivary MMP-8 levels in 
RA patients regardless the duration of RA. 
  
Key words:  Matrix metalloproteinases, saliva, periodontitis, rheumatoid arthritis 
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Introduction 
 
Rheumatoid arthritis (RA) and periodontitis are both inflammatory diseases with progressive 
chronic nature. Numerous earlier studies have addressed the association and causality of these 
diseases (Araújo, Melo, & Lima, 2015; Mikuls et al., 2012; Berthelot & Le Goff, 2010; Payne, 
Golub, Thiele & Mikuls, 2015). Porphyromonas gingivalis is reported actually to trigger RA 
through protein citrullination (Mikuls et al., 2012). This bacterium has been suggested to contribute 
to the development of RA through the citrullination of arginine residuals by endogenous 
peptidylarginine deiminase enzyme (Routsias, Goules, Goules, Charalampakis & Pikazis, 2011). 
Matrix metalloproteinases (MMPs) are a group of genetically separate but structurally related 
proteinases having  a role in normal and pathological tissue regenerating, but also in inflammatory 
tissue destruction (Nukarinen et al., 2016). They are detected in crevicular and oral fluids and also 
in synovial fluid related to periodontal and rheumatic inflammation, respectively (Sorsa et al., 2006; 
Tchetverikov et al., 2004). The plurality and overflow of MMPs may produce pathological tissue 
loss leading to increased MMPs and TIMPs ratio in saliva/oral fluid (Sorsa et al., 2006) and 
synovial fluid in inflamed joint (Tchetverikov et al., 2004). MMP-8 is the major collagenolytic 
MMP affecting gingiva and oral fluids in periodontitis originating mainly from polymorphonuclear 
neutrophils.  MMP-8 can efficiently degrade both type I collagen in the diseased periodontium and 
type II collagen in the diseased joint cartilage (Sorsa, Uitto, Suomalainen, Vauhkonen & Lindy, 
1988; Hasty, Jeffrey, Hibbs & Welgus,  1987). Salivary MMP-8 has been suggested as a biomarker 
in the monitoring of periodontitis (Sorsa et al., 2010; Nwhator et al., 2014; Heikkinen et al., 2016; 
Sorsa et al., 2016; Rathnayake, Gieselmann, Heikkinen, Tervahartiala & Sorsa, 2017; Sorsa, 
Gieselmann, Arweiler & Hernandez, 2017). 
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Since the 1990s the pharmacotherapy of RA has been revolutionized with early initiation of 
conventional disease modifying anti-rheumatic drugs (DMARDs) and with the discovery and use of 
biologic DMARDs (Smolen et al., 2014). Our knowledge about the effect of biological DMARDs 
in the oral cavity and on salivary MMP-8 is very limited. Use of anti-TNF-α antibody has been 
reported to have an influence on salivary biomarkers in RA patients [interleukin-1β (IL-1β), tumor 
necrosis factor-α (TNF-α) but not MMP-8)] (Mirrielees et al., 2010). With this background, we 
investigated whether the introduction of DMARDs, synthetic or biologic, has an impact on salivary 
MMP-8 levels and if the MMP-8 levels and MMP-8/TIMP-1 ratio in saliva associate with 
periodontal findings in RA under the treatment, either with conventional or biological DMARDs. 
We previously described that the patients even with early, untreated disease had poor periodontal 
health (Äyräväinen et al., 2017). Earlier, Monsarrat et al., (2013) reported improved RA disease 
activity scores among RA patients after periodontal treatment. Thus, the impact of DMARDs on 
salivary biomarkers and the possibility to use salivary MMP-8 as a biomarker when assessing 
periodontal disease and its treatment might have practical implications among patients with RA.  
We hypothesized that the MMP-8 concentrations and MMP-8/TIMP-1 ratio in saliva differ between 
the various RA patient groups and are modified under treatment with different DMARDs. 
 
Materials and Methods 
Study design 
We invited RA patients from Department of Rheumatology at the Helsinki University Hospital to 
participate in this prospective follow-up study. Study groups consisted of 53 untreated early RA 
(ERA) patients and 28 chronic RA (CRA) patients with inadequate response to synthetic DMARDs. 
Control subjects (n=43) of same age, gender and from same living area as the RA patients were 
selected from the national database (Statistics Finland). The original study plan was to collect 50 
ERA patients, 50 CRA patients and 50 population controls for both of these patient groups, i.e. a 
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total of 200 subjects. However, due to the strict inclusion criteria and other practical issues, we 
could not recruit consecutive patients. Many candidates also refused to participate this study for 
practical or personal reasons.  The population controls were selected to be representative controls 
for ERA and CRA patients.   
 
 The study protocol as well as patients and the control subjects in detail have been earlier described 
(Äyräväinen et al., 2017). In brief, rheumatological and oral examinations in RA patients were 
conducted twice, first at baseline and later, after initiation of new DMARD treatments, with a mean 
follow-up of 15.9±6.1 months. After the first examinations, ERA patients started treatment with 
synthetic DMARDs consisting of methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine 
(HCQ) and leflunomide (LEF) in various combinations. CRA patients started their first biological 
DMARDs comprising TNF-α inhibitors or non-TNF-α biologicals mainly combined with ongoing 
treatment with MTX. Control participants were examined once. 
 
We included RA patients between the ages of 18-70. Rheumatological and dental examinations 
were conducted by one rheumatologist and one dentist blinded from the oral and clinical conditions 
of the patients, respectively. The dental examinations were conducted in the Department of Oral and 
Maxillofacial Diseases.  The study participants gave written informed consent to participate in the 
study. The study protocol had been approved by the independent review board of the Helsinki and 
Uusimaa Hospital District (no 240/2004, date 16.6.2004), and the study was carried out according 
to the principles of the Declaration of Helsinki.  
 
Study population 
The ERA patients were mostly female (85%) with a mean (± SD) age of 51±15 years. The 
symptoms of RA had been present for 10.4±17.1 months. The CRA patients also were mostly 
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female (82%) with a mean age of 52±11 years. They had chronic disease with a mean duration of 
RA of 176±116.8 months. The patients met the criteria for RA according to the 1987 classification 
criteria (Arnett et al., 1988). The mean age of the control participants (88% were women) was 
56±13 years. During the study 6 ERA patients and 2 CRA patients interrupted the study for 
personal reasons. One ERA patient died between the dental and rheumatological re-examinations.   
 
Periodontal parameters and inflammatory burden 
Dental examination with panoramic jaw tomograms and bite-wing x-rays was recorded of all study 
participants. The number of teeth examined was 28, since third molars were excluded in the 
recording (Oral Health Surveys Basic Methods, 1997). In the case of dental problems, the study 
participants were advised to visit their dentists during the follow-up. Of the ERA patients, 45.7 % 
reported having periodontal treatment during the follow-up, compared with 44.0% of the CRA 
patients, respectively. However, we had no detailed data regarding the dental treatments given. 
 
Periodontal parameters bleeding on probing (BOP) and probing depth (PD) (at four sites per every 
tooth) were recorded (Ainamo & Bay, 1975; Nieminen et al., 1995). Periodontal inflammatory 
burden index (PIBI) was assessed as described previously (Lindy, Suomalainen, Mäkelä, &Lindy, 
2008).  
 
Unstimulated (USFR) and stimulated (SSFR) saliva samples were collected for 5 minutes. Paraffin 
wax chewing was used for stimulation of saliva secretion. Flow rate was recorded as milliliters per 
min (Navazesh & Kumar, 2008; Villa, Connell & Abati, 2015).   
 
MMP-8 in saliva 
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Analysis of MMP-8 levels in saliva was performed as described and reported previously (Hemmilä, 
Dakubu, Mukkala, Siitari & Lövgren 1984; Hanemaaijer et al., 1997; Mäntylä et al., 2003). The 
detection limits and inter-assay coefficients of variation were 0.08 ng/mL and 7.1 % for MMP-8 
(Rathnayake et al., 2013). 
 
TIMP-1 in saliva 
TIMP-1analysis was conducted using an enzyme-linked immunosorbent assay (ELISA) kit 
according to the manufacturer’s instructions (R&D Systems Europe Ltd, Abingdon, UK). The 
detection limits and inter-assay coefficients of variation were 7.8 pg/mL and 3.4 % for TIMP-1 
(Rautelin et al., 2009).  
 
Rheumatological examinations 
The number of swollen and tender joints (66/68 joint count and 28 joint count) were recorded.  RA 
patients gave estimation of disease activity by the patient`s global assessment (PGA) scale (100 mm 
visual analogue scale). Disease Activity Score (DAS28) was calculated from the number of tender 
and swollen joints (28-joint count), patient global assessment (PGA) and erythrocyte sedimentation 
rate (ESR) (Prevoo et al., 1995). Analyses from blood samples were conducted for rheumatoid 
factor (RF), anticyclic citrullinated peptide antibody (CCPAb), plasma C reactive protein (CRP), 
and ESR. Response for RA treatment was evaluated according to the European League Against 
Rheumatism (EULAR) criteria (van Gestel et al., 1996; Fransen & van Riel 2005). 
 
Antirheumatic medication 
After the baseline examinations, synthetic DMARDs comprising MTX, SSZ, HCQ and LEF either 
as monotherapy or in different combinations (mono-, double or triple therapy) were started to ERA 
patients. Seventeen (37.0 %) of the ERA patients were on monotherapy (mostly MTX, two patients 
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had LEF), 18 (39.1 %) were on double DMARD therapy (MTX+SSZ, MTX+HCQ, SSZ+HCQ or 
combinations with LEF) and 9 (19.1 %) were on triple DMARD therapy (MTX+SSZ+HCQ). 
Furthermore, low-dose (≤10 mg prednisolone equivalent) oral glucocorticoids were used by 28.3 % 
of the ERA patients.  
 
Before the introduction of biological DMARDs, 8 (28.6 %) of CRA patients were on monotherapy, 
11 (39.3 %) on double therapy and 7 (25.0 %) on triple therapy. After the baseline investigations, 
the CRA patients started biologic DMARDs consisting of TNF-α inhibitors: adalimumab in 9/27 
(33.3 %) of patients, etanercept in 17/27 (63.0 %), golimumab in 2/27 (7.4 %) and certolizumab 
pegol in 1/27 (3.7 %) of patients; or non-TNF-α biologicals: interleukin-1 inhibitor anakinra in 1/27 
(3.7 %) of patients, or anti-B-cell antibody rituximab in 2/27 (7.4 %) of patients, mainly combined 
with MTX. Three CRA patients were on LEF. The biologic DMARDs could be changed if 
indicated during the follow-up. At follow-up examination, 85.2 % of the CRA patients were on a 
TNF-α inhibitor and 7.4 % were on a non-TNF-α biological. 74.1 % of the CRA patients used low-
dose prednisolone. 
 
Both ERA and CRA patients were treated with intra-articular injections and non-steroidal anti-
inflammatory drugs (NSAIDs) to suppress joint swelling and pain. 
 
Statistical methods 
The results are given as medians with IQRs (25–75%; non-parametric distribution) or in means with 
SDs (parametric distribution). Non-parametric Kruskal-Wallis test and Mann-Whitney U-test were 
used when comparing independent samples, and Wilcoxon signed rank test with related samples to 
compare differences between baseline and after follow-up results. Correlations for nonparametric 
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data were analyzed by the Spearman rank correlation coefficients. Statistical analyses were 
performed with SPSS V.24 and p<0.05 was considered as statistically significant.  
  
Results 
Baseline characteristics of the study groups are given in Table 1. RA patients were mostly positive 
for CCPAb and RF and they suffered from active disease as assessed by DAS28. ESR and CRP 
values were significantly higher in both RA groups compared with the controls (Table 1). 
Periodontal findings, recorded by BOP, PD≥4mm and PIBI, were more frequent in both RA groups 
compared with the controls. BOP was significantly higher (p=0.032) at baseline in ERA group vs. 
CRA group, but no more at follow-up (p= 0.383). No statistically significant difference with respect 
to PD≥4mm and PIBI was found at baseline (p=0.511 and p=0.273, respectively) or at follow-up 
(p=0.115; p=0.143, respectively) between ERA and CRA patients. Salivary MMP-8 concentration 
and MMP-8/TIMP-1 ratio were significantly higher in ERA group at baseline compared with CRA 
and control groups, as given in Table 1. 
Study parameters in ERA group with respect to synthetic DMARDs  
RA disease activity decreased significantly in each of the medication groups during the study.  
Number of teeth decreased significantly in the double therapy group (28 [23-28] to 27 [22-28], 
p=0.034). CRP decreased significantly from 7 (4-22) to 4 (2-6), (p=0.002). The number of 
PD≥4mm [6 (3-14) to 12 (5-18), p=0.020] and the median of PIBI [6 (3-14) to 12 (6-19), p= 0.016] 
increased significantly in the monotherapy group during the study. At follow-up, the MMP-
8/TIMP-1 ratio was significantly higher in patients with triple therapy compared with mono- and 
double therapy groups (Table 2). In other study parameters, there were no significant changes 
between the baseline and follow-up values within each medication group or between the medication 
groups when comparing the groups at baseline or after follow-up (Table 2). 
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Study parameters in CRA group with respect to biological DMARDs  
During the follow-up, CRP decreased significantly in patients starting a biological DMARD on the 
background of monotherapy [6 (2-24) to 2 (2-10), p= 0.028] and DAS28 score diminished 
significantly in the group with background of DMARD triple therapy [2.9 (2.3-4.2) to 1.7 (1.1-2.1), 
p= 0.028]. BOP also decreased significantly: 19 (7-25) to 11 (3-19), (p= 0.028). No other 
significant findings were observed in the study parameters among CRA patients using combinations 
of synthetic DMARDs combined with biological medication during the study (Table 3). 
 
In CRA patients, a significant correlation was found between salivary MMP-8 values and MMP-
8/TIMP-1 ratio and PIBI, see Table 4. Further, Table 5 gives the concentrations of salivary MMP-8 
and the ratios of salivary MMP-8/TIMP-1 with respect to medians of PIBI in both RA groups at 
baseline and after follow-up and in controls. The MMP-8/TIMP-1 ratio was significantly higher at 
baseline in ERA patients with higher PIBI values. In CRA patients, the concentration of MMP-8 
and the MMP-8/TIMP-1 ratio were significantly elevated with higher PIBI values at baseline and 
after follow-up. Also, the concentration of MMP-8 and the MMP-8/TIMP-1 ratio associated with 
higher PIBI values in controls (Table 5). 
 
When comparing the differences of salivary MMP-8 concentration in the CRA patients between the 
subgroups in relation to the used biologic medication (adalimumab, etanercept, golimumab, 
certolizumab pegol, anakinra, rituximab), or in relation to the TNF-α inhibitors versus the non-
TNF-α inhibitors, no significant differences were observed. Neither did the use of glucocorticoids 
seem to affect salivary MMP-8 concentration in the RA patients (data not shown). 
 
Discussion  
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To the best of our knowledge, this is the first report on the impact of DMARDs on salivary MMP-8 
values in RA patients in a prospective follow-up scheme. RA patients had poorer periodontal health, 
assessed by BOP and PIBI, when compared with controls. Significantly elevated BOP and PIBI 
reflected in higher salivary MMP-8 levels already at the early stage of RA. Compared with CRA 
patients, BOP was significantly increased in ERA group at baseline, but no other significant 
differences were observed in periodontal parameters between ERA and CRA groups during the 
study. Contrary to our expectation, the use of antirheumatic medications (either synthetic or 
biologic) did not affect salivary MMP-8 values of the RA patients. Although synthetic DMARDs 
remarkably decreased inflammation in joints during the follow-up, no significant changes were 
observed in salivary MMP-8 levels after the follow-up of 16 months. This result remained the same 
also after dividing the patients into subgroups according to mono-, double or triple therapy; hence 
the synthetic DMARDs did not seem to have any effect in this regard. Thus, the synthetic 
DMARDs did not seem to disturb the evaluation of periodontal health by the salivary MMP-8 
analysis. 
 
Hosts innate, inflammatory and adaptive immune response to the microbial invasion affect to the 
development of periodontitis with the contribution of behavioral, environmental and genetic factors 
(Silva et al., 2015). Further, a new model of pathogenesis explains that periodontitis originates by a 
synergistic and dysbiotic microbial community (polymicrobial synergy and dysbiosis model, PSD 
model) rather than by a select bacterial complex (Hajishengallis & Lamont, 2012). As the 
periodontal microbiota change from symbiotic to a dysbiotic stage, abundance of characteristic 
cytokines and inflammatory mediators are filtered to the periodontal tissue and lead to tissue 
destruction. 
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We have recently reported that in this study population, salivary MMP-8 associated with 
periodontal parameters (Äyräväinen et al., 2018). Here we show that salivary MMP-8 levels were 
increased already at the beginning of the study in ERA patients probably indicating poor 
periodontal health, which even got worse in the monotherapy group during the follow-up. This may 
also reflect the progressive RA associated with active inflammation, revealing the continuous and 
ongoing inflammatory burden in the joints, which, in fact, may also systematically increase the 
salivary MMP-8 levels via increased serum concentrations of MMP-8 (Ben-Aryeh et al., 1978).  
 
In the CRA patients, the salivary MMP-8 concentrations correlated with PIBI scores similarly to 
what was observed in the controls. After the introduction of the biologic DMARDs, the salivary 
MMP-8 levels increased, even though not significantly. This might be due to ongoing 
rheumatological inflammation but also because of the patient´s susceptibility to infection due to the 
biologic medication. This trend was especially clearly observed in those patients who received 
double and triple therapy together with the biologic DMARDs (TNF-α inhibitor, mostly 
adalimumab or etanercept). In further analysis, when chronic RA patients were divided into 
subgroups (adalimumab, etanercept, golimumab, certolizumab pegol, anakinra or rituximab) 
according to the used biologic medications, to find out whether the medications influenced the 
association between salivary MMP-8 concentrations and PIBI scores, or if they linked to the 
number of periodontal pockets, no significant associations were detected. Neither any significant 
differences were found between the different classes of biological DMARDs when TNF-α 
inhibitors or non-TNF-α inhibitors had been used. 
 
Recently, a novel active matrix metalloproteinase (aMMP8) point of care/chair-side mouth-rinse 
test has been demonstrated to quantitatively identify periodontal disease when the patient has at 
least two deep periodontal pockets (Nwhator et al., 2014; Heikkinen et al., 2016; Sorsa et al., 2017). 
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It is important to diagnose periodontitis since RA patients often have diminished manual dexterity 
and thus difficulties in maintaining satisfactory daily oral hygiene; they consequently are liable to 
periodontitis. This, in turn, may cause systemic low-grade inflammation detrimental to the patients 
with RA, as earlier discussed.  
 
The strength of the current prospective study was that we have a well-characterized patient 
population consisting of DMARD-naïve patients with early RA and of patients with chronic active 
RA whom we have restudied after the introduction of synthetic or biological DMARDs. The 
weakness, however, was the comparatively small number of patients although we recruited all 
eligible patients during the set timeline. A lack of detailed information of periodontal treatment 
received by the patients during the follow-up period was also a limitation of this study. 
Furthermore, for practical reasons, the control participants could only be examined once. Therefore, 
the current results could only partly confirm our study hypothesis.  
 
In conclusion, RA patients regardless their disease stage are exposed to inflammation, such as 
periodontal disease. Antirheumatic medications, synthetic or biologic drugs, seemed to have no 
significant relevance with respect to periodontal diagnosis. However, more studies with larger 
patient materials are needed for further conclusion about the effect of DMARDs on saliva/oral fluid 
biomarkers in RA patients with periodontitis.  
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Table 1. Baseline characteristics of the study groups 
                                             Early RA                                                               Chronic RA                                                                       Controls   
                               Baseline              Follow-up                                  Baseline                       Follow-up                        
                               N=53                    N=47                           p¶             N=28                            N=26                               p¶             N=43                      p¶¶     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results are presented as number of patients (%) or median with interquartile range (IQR).N, number of patients; RA, rheumatoid arthritis; CRA, chronic RA;  
ERA, early RA; RF, rheumatoid factor; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CCPAb, anticyclic citrullinated  
peptide antibody; DAS28, disease activity score (28-joint); BOP, bleeding on probing; PD, pocket depth; PIBI, periodontal inflammatory burden index. 
‡ data missing from 5 ERA patients and from 9 CRA patients. ‡‡ at baseline data missing from 3 ERA patients, after follow-up data missing from 7 ERA and from 3 CRA 
patients. 
*p value by Chi-Square crosstabulation;   ¶ p value by nonparametric Wilcoxon test comparing related samples between baseline and follow-up. ¶¶ p value by nonparametric 
Mann-Whitney U-test or Kruskal-Wallis test for other variables comparing study groups at baseline. Statistically significant p values are shown in bold. 
RF positive 42 (79.2)   18 (69.2)   3 (8.1) <0.001* 
 
CCPAb positive ‡  37 (77.1)   15 (78.9)    0.574* 
 
ESR, mm/h 
 
20 (11–34) 9 (5-16) <0.001 20 (9-46) 16 (7-31) 0.038 2 (2-10) <0.001 
CRP, mg/l  6 (3-14) 3 (2-6) 0.001 18 (5-30) 10 (2-21) 0.012 2 (2-3) <0.001 
 
DAS28 4.0 (3.2–4.8) 
 
2.4 (1.7–2.9) <0.001 4.1 (3.0–4.9) 3.1 (2.0–3.9) 0.003  0.974 
Number of teeth 27 (23–28) 27 (22–28) 0.024 27 (22–28) 27 (22–28) 0.317 27 (25–28) 0.628 
BOP per cents 
sites 
 
15 (10–26) 13 (6-21) 0.124 9 (5-19) 8 (3-22) 0.903 4 (2-8) <0.001 
 
PD≥4mm ‡‡ 
 
PIBI 
45 (84.9) 
 
10 (3-18) 
43 (81.1) 
 
9 (6-19) 
0.250 
 
0.907 
25 (89.3) 
 
5 (3-15) 
21 (75.0) 
 
4 (1-16) 
1.000 
 
0.856 
28 (65.1) 
 
1 (0-3) 
0.012 
 
<0.001 
Salivary MMP-8, 
ng/ml 
 
MMP-8/TIMP-1 
ratio 
311.2  
(105.6–524.8) 
 
2.5 
(0.9-5.5) 
 
221.0 
(128.1–452.8) 
 
1.9 
(1.2–4.0) 
 
0.800 
 
 
0.775 
114.8 
(40.8–290.8) 
 
1.0 
(0.6-2.3) 
175.6 
(75.0–391.8) 
 
1.2 
(0.7-2.8) 
 
0.221 
 
 
1.000 
113.6 
(76.0–226.8) 
 
1.3 
(0.8-2.7) 
 
0.010 
 
 
<0.001 
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    Table 2. Parameters in ERA patients at baseline and after follow-up with respect to initiation of synthetic DMARDs  
                                                                                                                                                                                                                                                 
ERA, early rheumatoid arthritis; DMARDs, disease modifying antirheumatic drugs; DAS28, disease activity score (28 joint); CRP, C reactive protein; N, number; BOP, 
bleeding on probing; PD, pocket depth; PIBI, periodontal inflammatory burden index; MMP-8, matrix metalloproteinase-8; TIMP-1, tissue inhibitor for MMPs. Results are 
medians with interquartile range (IQR).  
¶ p value by nonparametric Wilcoxon test comparing related samples between baseline and follow-up. 
¶¶ p value by nonparametric Kruskal-Wallis test comparing patients at baseline prior to start of monotherapy, double therapy, or triple therapy with synthetic DMARD(s). 
¶¶¶ p value by nonparametric Kruskal-Wallis test comparing monotherapy, double therapy and triple therapy groups after follow-up, of a mean of 15.9±6.1 months.  
p value significant at the level 0.05. Statistically significant p values are shown in bold.  
 
 
  
Parameter         Monotherapy N=17  
       baseline      follow-up 
 
p¶ 
  Double therapy N=18 
baseline           follow-up 
 
p¶ 
       Triple therapy N=9 
    baseline          follow-up 
 
p¶ 
 
p¶¶ 
 
p¶¶¶ 
 
DAS28 3.5 (2.6–5.5) 2.4 (1.5–2.9) 0.003 4.3 (3.4–5.0) 2.4 (1.8–3.0) <0.001 4.4 (3.0–4.7) 2.7 (1.2–3.3) 0.043 0.350 0.947 
 
Duration of  
symptoms, years 
0.4 (0.3-1.1)   0.3(0.3-0.7)   0.4 (0.3-1.9)   0.391  
 
CRP, mg/ml 5 (2-14) 4 (2-12) 0.688 7 (4-22) 4 (2-6) 0.002 3 (3-13) 2 (2-3) 0.090 0.414 0.136 
 
Number of teeth 23 (20–28) 23 (20–28) 1.000 28 (23–28) 27 (22–28) 0.034 27 (22–28) 27 (21–28) 0.317 0.594 0.781 
 
BOP 13 (9-35) 14 (6-22) 0.463 16 (8-27) 14 (4-24) 0.649 21 (10–27) 12 (7-14) 0.068 0.956 0.619 
 
PD≥4mm 6 (3-14) 12 (5-18) 0.020 11 (4-30) 9 (3-31) 0.697 14 (6-21) 10 (7-16) 0.105 0.407 0.904 
 
PIBI 6 (3-14) 12 (6-19) 0.016 11 (4-31) 9 (3-31) 0.568 14 (6-21) 10 (7-16) 0.105 0.407 0.898 
 
Salivary MMP-8,  
ng/ml 
235.2 
(96.6–401.2) 
268.0 
(165.0–475.6) 
 
0.463 
166.6 
(62.8–355.1) 
140.4 
(81.0–272.0) 
 
0.469 
386.4 
(248.2–777.8) 
222.8 
(175.8–666.2) 
 
0.767 
 
0.141 
 
0.163 
 
MMP-8/TIMP-1 
ratio 
1.6 (0.7-3.8) 2.5 (1.9–4.7) 0.163 1.0 (0.5-3.3) 1.2 (0.5-2.1) 0.427 4.4 (2.8–6.2) 2.9 (1.5–4.5) 0.260 0.039 0.007 
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Table 3. Parameters in CRA patients at baseline and after follow-up with respect to initiation of biological DMARDs 
 
CRA, chronic rheumatoid arthritis; DMARDs, disease modifying antirheumatic drugs; DAS28, disease activity score (28 joint); CRP, C reactive protein; N, number; BOP, 
bleeding on probing; PD, pocket depth; PIBI, periodontal inflammatory burden index; MMP-8, matrix metalloproteinase-8; TIMP-1 tissue inhibitor for MMPs. Results are 
medians with interquartile range (IQR). 
¶ p value by nonparametric Wilcoxon test comparing related samples between baseline and follow-up. 
¶¶ p value by nonparametric Kruskal-Wallis test comparing patients at baseline grouped according to the ongoing mono therapy, double therapy or triple therapy with synthetic 
DMARDs. 
¶¶¶ p value by nonparametric Kruskal-Wallis test comparing patients according to the background use of synthetic DMARDS as monotherapy, double therapy or triple therapy 
after follow-up on biological DMARDs with a mean of 15.9±6.1 months.  
p value significant at the level 0.05. Statistically significant p values are shown in bold. 
 
 
 
Parameter         Monotherapy N= 8  
      baseline          follow-up 
 
 p¶ 
      Double therapy N= 11 
     baseline          follow-up 
 
p¶ 
       Triple therapy N=7 
      baseline         follow-up 
 
p¶ 
 
p¶¶ 
 
p¶¶¶ 
 
DAS28 4.6 (2.3–4.9) 2.8 (1.8–4.4) 0.600 4.3 (3.7–5.9) 3.6 (2.9–4.7) 0.051 2.9 (2.3–4.2) 1.7 (1.1–2.1) 0.028 0.085 0.068 
Duration of 
symptoms, years 
21.4 (11.7–23.9)   7.7 (7.0–18.8)   10.7 (1.8–14.7)   0.236  
CRP, mg/ml 6 (2-24) 2 (2-10) 0.028 28 (15–55) 15 (6-32) 0.059 17 (2-29) 7 (2-19) 0.144 0.089 0.084 
Number of teeth 26 (21–28) 26 (21–28) 1.000 26 (21–28) 25 (18–28) 1.000 28 (26–28) 28 (26–28) 0.317 0.182 0.302 
BOP 19 (7-25) 11 (3-19) 0.028 8 (6-15) 5 (2-24) 0.889 5 (3-21) 11 (2-37) 0.138 0.361 0.970 
PD≥4mm 5 (2-20) 5 (2-17) 0.399 4 (0.15) 3 (1-14) 0.674 7 (4-15) 6 (1-23) 0.752 0.819 0.848 
PIBI 5 (2-21) 5 (2-17) 0.399 4 (0-15) 3 (1-14) 0.674 7 (4-15) 9 (2-35) 0.500 0.825 0.743 
Salivary MMP-8, 
ng/ml 
192.2 
(42.6–303.1) 
184.8 
(58.8–375.9) 
 
0.899 
110.8 
(40.8–456.4) 
156.8 
(75.0–333.7) 
 
0.721 
114.8 
(75.2–180.4) 
335.8 
(164.0–708.0) 
 
0.166 
 
0.558 
 
0.093 
 
MMP-8/TIMP-1 
ratio 
1.0 
(0.6-3.5) 
1.0 
(0.5-3.2) 
 
0.161 
1.5 
(0.5-2.3) 
1.2 
(0.8-2.6) 
 
0.799 
0.9 
(0.7-1.5) 
2.1 
(1.0–6.1) 
 
0.345 
 
0.491 
 
0.290 
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Table 4. Correlation of salivary MMP-8 concentration and MMP-8/TIMP-1 ratio with periodontal inflammatory burden   
 
                                            ERA________________                                                         CRA______                                                                  Controls 
 PIBI  at baseline 
Rs 
p¶ 
 
PIBI  
after follow-up 
Rs 
p¶ 
correlation  
for the change 
Rs 
p¶ 
PIBI  
at baseline 
Rs 
p¶ 
PIBI  
after follow-up 
Rs 
p¶ 
correlation  
for the change 
Rs 
p¶ 
 
PIBI  
Rs 
p¶ 
MMP-8, 
ng/ml 
0.298 
0.035 
0.185 
0.229 
0.002 
0.990 
0.720 
<0.001 
0.585 
0.002 
0.138 
0.529 
0.391 
0.010 
 
MMP-8/TIMP-1 
ratio 
0.301 
0.034 
0.220 
0.156 
0.043 
0.787 
0.685 
<0.001 
0.610 
0.002 
– 0.068 
0.756 
0.391 
0.010 
        
MMP-8, matrix metalloproteinase-8; TIMP-1, tissue inhibitor for MMPs; PIBI, periodontal inflammatory burden; ERA, early rheumatoid arthritis; 
CRA, chronic rheumatoid arthritis 
¶correlation Rs Spearman correlation; 2-tailed p value significant at the 0.05 level 
Statistically significant p values are shown in bold. 
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       Table 5. Salivary MMP-8 concentration and MMP-8/TIMP-1 ratio compared to periodontal inflammatory burden in the study groups during the study 
 
                                                    ERA                                                             CRA                                                   Controls                                      
                                   PIBI                    PIBI                                  PIBI                 PIBI                                  PIBI              PIBI 
                       
 
MMP-8, matrix metalloproteinase-8; TIMP-1, tissue inhibitor for MMPs; PIBI, periodontal inflammatory burden; RA rheumatoid arthritis 
PIBI median in ERA at baseline 10, after follow-up 9; for the change from baseline to follow-up 0; in CRA at baseline 5, after follow-up 4;for the change from 
baseline to follow-up 0; controls 1. Results are medians with interquartile range (IQR). 
¶p value by nonparametric Mann-Whitney U-test comparing differences between ≤median and > median in each study group 
¶¶p value by nonparametric Kruskal-Wallis test comparing differences between Era, Cra and control groups when PIBI≤median 
¶¶¶p value by nonparametric Kruskal-Wallis test comparing differences between Era, Cra and control groups when PIBI>median 
Statistically significant p values are shown in bold. 
 
 
 ≤ median >median p
¶ ≤ median >median p¶ ≤ median >median p¶ p¶¶ p¶¶¶ 
MMP-8 
  baseline 
185.2 
(101.6–385.2) 
356.0 
(189.6–718.0) 
 
0.124 
54.0 
(35.0–138.2) 
204.8 
(109.7–636.3) 
 
0.008 
102.8 
(64.0–172.0) 
151.4 
(108.8–538.5) 
 
0.008 
 
0.003 
 
0.228 
 
MMP-8 
  follow-up 
216.4 
(103.6–584.0) 
252.0 
(172.6–390.0) 
 
0.404 
82.4 
(41.0–159.6) 
407.6 
(177.3–636.2) 
 
0.001    
 
0.008 
 
0.246 
 
MMP-8 
  change 
16.8 
(-85.6–159.0) 
8.6 
(-138.9–118.1) 
 
0.417 
– 1.6 
(-48.0–76.8) 
20.2 
(-30.4–207.7) 
 
0.321    
 
0.701 
 
0.250 
 
MMP-8/TIMP-1 
  baseline 
1.5 
(0.8-3.1) 
3.5 
(1.6–6.0) 
 
0.037 
0.6 
(0.4-1.4) 
1.5 
(0.9-3.8) 
 
0.014 
0.9 
(0.5-1.7) 
2.2 
(0.9-3.8) 
 
0.009 
 
0.023 
 
0.165 
MMP-8/TIMP-1 
  follow-up 
1.6 
(0.9-3.6) 
2.4 
(1.3–4.2) 
 
0.198 
0.8 
(0.5-1.2) 
2.8 
(1.0–4.6) 
 
0.004    
 
0.031 
 
0.793 
MMP-8/TIMP-1 
   change 
0.1 
(-1.3–1.4) 
0.1 
(-1.3–0.7) 
 
0.722 
– 0.1 
(-0.8-0.3) 
– 0.1 
(-0.9-1.6) 
 
0.780    
 
0.600 
 
1.000 
